CD274 and urinary bladder carcinoma: To select patients with a high response to ICI therapy, we performed unsupervised clustering analysis using gene expression profiling from bladder cancer patients treated with the PD-L1 inhibitor atezolizumab (the IMvigor 210 trial [11]).